Literature DB >> 15949565

Chromosome 7 abnormalities are common in chordomas.

Petter Brandal1, Bodil Bjerkehagen, Håvard Danielsen, Sverre Heim.   

Abstract

Chordomas are malignant bone tumors most often located in the axial skeleton. The estimated 5-year patient survival rate is between 50 and 80%. The cytogenetic and molecular genetic features of chordomas are largely unknown but, from what can be seen, appear to be complex. Near-diploid karyotypes have been detected by G-banding analysis, and comparative genomic hybridization (CGH) has revealed losses of or from chromosome arms 1p and 3p, as well as partial or whole copy number gains of chromosomes 7 and 20. We provide additional molecular cytogenetic information about six sacral chordomas examined by CGH and interphase fluorescence in situ hybridization (IP-FISH). By CGH, gains of chromosomal areas 1q23 approximately q24 (three tumors), 7p21 approximately p22 (three tumors), 7q (four tumors), and 19p13 (three tumors), as well as loss of chromosomal segment 9p22 approximately p23 (three tumors), were the most frequently observed imbalances. These results are concordant with earlier CGH data, although loss of or from chromosome arms 1p and 3p was not found as frequently in this series; both were detected in only one tumor. IP-FISH confirmed the CGH findings and showed that chromosome 7 was polysomic in four of the tumors. All these samples had trisomic and tetrasomic clones for chromosome 7, and two of them had pentasomic clones as well.

Entities:  

Mesh:

Year:  2005        PMID: 15949565     DOI: 10.1016/j.cancergencyto.2004.11.016

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  14 in total

Review 1.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

2.  Extra-axial chordomas.

Authors:  S Evans; Z Khan; L Jeys; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2016-05       Impact factor: 1.891

3.  Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.

Authors:  Beatriz A Walter; Maria Begnami; Vladimir A Valera; Mariarita Santi; Elisabeth J Rushing; Martha Quezado
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

Review 4.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 5.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

6.  MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.

Authors:  Florian Grabellus; Margarethe J Konik; Karl Worm; Sien-Yi Sheu; Johannes A P van de Nes; Sebastian Bauer; Werner Paulus; Rupert Egensperger; Kurt W Schmid
Journal:  Tumour Biol       Date:  2010-03-06

Review 7.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

8.  Frequent activation of EGFR in advanced chordomas.

Authors:  Barbara Dewaele; Francesca Maggiani; Giuseppe Floris; Michele Ampe; Vanessa Vanspauwen; Agnieszka Wozniak; Maria Debiec-Rychter; Raf Sciot
Journal:  Clin Sarcoma Res       Date:  2011-07-25

9.  Genome-wide analyses of gene expression during mouse endochondral ossification.

Authors:  Claudine G James; Lee-Anne Stanton; Hanga Agoston; Veronica Ulici; T Michael Underhill; Frank Beier
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

Review 10.  From notochord formation to hereditary chordoma: the many roles of Brachyury.

Authors:  Yutaka Nibu; Diana S José-Edwards; Anna Di Gregorio
Journal:  Biomed Res Int       Date:  2013-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.